Mustgrow biologics corp. Announces filing of final base shelf prospectus
22 April 2022, Canada: MustGrow Biologics Corp. announces that it has filed a final short form base shelf prospectus (the “Shelf Prospectus“) with securities regulatory authorities in each province of Canada.
“The Shelf Prospectus will provide us with greater flexibility to access capital on an expedited basis if and when required during the 25 month period it is expected to be effective,” said Corey Giasson, President and Chief Executive Officer of MustGrow. “While we have no immediate plans to draw capital down under the Shelf Prospectus, it will be available as a tool to help grow our business and further execute on our strategic plan.“
The Shelf Prospectus enables the Company to offer common shares, warrants, units, debt securities, subscription receipts or any combination thereof for aggregate gross proceeds of up to $40 million during the 25 month period the Shelf Prospectus is effective.
If the Company proceeds with an offering of securities under the Shelf Prospectus, the specific terms, the proposed use of proceeds and other matters related to such offering will be set out in a prospectus supplement, which will be filed with all applicable Canadian securities regulatory authorities. The Company may also use the Shelf Prospectus in connection with an “at-the-market distribution” in accordance with applicable securities laws, which would permit securities to be sold on behalf of the Company through the Canadian Securities Exchange (or other applicable stock exchange) as further described in the applicable prospectus supplement. To date, no agreement has been entered into with respect to such a distribution.
Also Read: India targets 3,280 lakh tonnes food grain production in 2022-23
The Shelf Prospectus can be found under the Company’s profile on SEDAR at www.sedar.com.
This news release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities of the Company, nor will there be any offering or sale of such securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful absent registration or qualification of such securities under the applicable laws of any such jurisdiction, including the United States.